CN103721094A - 用于降血压的保健茶 - Google Patents
用于降血压的保健茶 Download PDFInfo
- Publication number
- CN103721094A CN103721094A CN201310461769.9A CN201310461769A CN103721094A CN 103721094 A CN103721094 A CN 103721094A CN 201310461769 A CN201310461769 A CN 201310461769A CN 103721094 A CN103721094 A CN 103721094A
- Authority
- CN
- China
- Prior art keywords
- fructus
- radix
- blood pressure
- herba
- tea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036772 blood pressure Effects 0.000 title claims abstract description 44
- 241001122767 Theaceae Species 0.000 title claims description 52
- 239000003814 drug Substances 0.000 claims abstract description 25
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 21
- 206010033546 Pallor Diseases 0.000 claims description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 18
- 241000180649 Panax notoginseng Species 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 18
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 17
- 235000006226 Areca catechu Nutrition 0.000 claims description 17
- 235000012239 silicon dioxide Nutrition 0.000 claims description 17
- 244000080767 Areca catechu Species 0.000 claims description 16
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 206010053615 Thermal burn Diseases 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 6
- 238000009826 distribution Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000000465 moulding Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 244000269722 Thea sinensis Species 0.000 abstract 3
- 244000012254 Canarium album Species 0.000 abstract 1
- 235000009103 Canarium album Nutrition 0.000 abstract 1
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 241000782535 Hypericum sampsonii Species 0.000 abstract 1
- 241000209035 Ilex Species 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 abstract 1
- 235000002294 Ilex volkensiana Nutrition 0.000 abstract 1
- 240000005779 Jasminum multiflorum Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 241001080798 Polygala tenuifolia Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 241000381592 Senegalia polyacantha Species 0.000 abstract 1
- 241000157352 Uncaria Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 235000013616 tea Nutrition 0.000 description 43
- 230000000694 effects Effects 0.000 description 37
- 210000004185 liver Anatomy 0.000 description 31
- 210000003734 kidney Anatomy 0.000 description 27
- 206010020772 Hypertension Diseases 0.000 description 26
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 230000001737 promoting effect Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 13
- 210000002216 heart Anatomy 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 208000002173 dizziness Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 208000009205 Tinnitus Diseases 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 231100000886 tinnitus Toxicity 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 230000004630 mental health Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- -1 chlorine ketone Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000000881 depressing effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-ACJLOTCBSA-N (R,R)-labetalol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 SGUAFYQXFOLMHL-ACJLOTCBSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- IQSFEAHJUMVILC-UHFFFAOYSA-N Isorhynchophyllic acid Natural products CCC1CN2CCC3(C2CC1C(=COC)C(=O)O)C(=O)Nc4ccccc34 IQSFEAHJUMVILC-UHFFFAOYSA-N 0.000 description 1
- DAXYUDFNWXHGBE-VKCGGMIFSA-N Isorhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-VKCGGMIFSA-N 0.000 description 1
- VCNYNWHVJKWJRQ-UHFFFAOYSA-N Isorhynchophylline Natural products CCC1=CN2CCC3(C2CC1C(=COC)C(=O)OC)C(=O)Nc4ccccc34 VCNYNWHVJKWJRQ-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- CQXADFVORZEARL-UHFFFAOYSA-N Rilmenidine Chemical compound C1CC1C(C1CC1)NC1=NCCO1 CQXADFVORZEARL-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004980 betanidine Drugs 0.000 description 1
- NIVZHWNOUVJHKV-UHFFFAOYSA-N bethanidine Chemical compound CN\C(=N/C)NCC1=CC=CC=C1 NIVZHWNOUVJHKV-UHFFFAOYSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 229960002320 celiprolol Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229950007942 dilevalol Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960003938 moxonidine Drugs 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000764 rilmenidine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004873 systolic arterial blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
SBp | DBp | |
服用前 | 157.32±10.03 | 95.49±3.91 |
服用后 | 136.17±8.22 | 83.19±2.01 |
组别 | n | 显效 | 有效 | 无效 | 总有效 |
治疗组 | 70 | 42(60.0) | 25(35.7) | 3(4.3) | 67(95.7) |
服用前 | 15.19±2.14 |
服用后 | 7.51±1.97 |
组别 | n | 显效 | 有效 | 无效 | 总有效 |
治疗组 | 70 | 40(57.1) | 27(38.6) | 3(4.3) | 67(95.7) |
SF(满分20分) | MH(满分20分) | QOL(满分130分) |
服用前 | 13.19±2.71 | 14.29±2.18 | 98.93±10.02 |
服用后 | 15.74±2.94 | 16.98±2.01 | 107.02±10.91 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310461769.9A CN103721094B (zh) | 2013-09-28 | 2013-09-28 | 用于降血压的保健茶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310461769.9A CN103721094B (zh) | 2013-09-28 | 2013-09-28 | 用于降血压的保健茶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103721094A true CN103721094A (zh) | 2014-04-16 |
CN103721094B CN103721094B (zh) | 2016-07-13 |
Family
ID=50445555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310461769.9A Expired - Fee Related CN103721094B (zh) | 2013-09-28 | 2013-09-28 | 用于降血压的保健茶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103721094B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104258135A (zh) * | 2014-09-23 | 2015-01-07 | 苏州市天灵中药饮片有限公司 | 用于降血压降血脂的保健软胶囊及其制备方法 |
CN104304596A (zh) * | 2014-11-16 | 2015-01-28 | 久美彭措 | 一种采用食用植物作为成分组合而成的降血糖代用茶的制备方法 |
CN105012385A (zh) * | 2015-07-28 | 2015-11-04 | 红河州吉昌生物科技有限公司 | 改进型补肝肾降血压胶囊 |
CN108617818A (zh) * | 2018-08-16 | 2018-10-09 | 李文霞 | 一种降血压的保健茶 |
CN109953152A (zh) * | 2017-12-22 | 2019-07-02 | 甘肃渭水源药业科技有限公司 | 一种用黄芪花作原料的花茶及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095952A (zh) * | 1993-06-04 | 1994-12-07 | 陈顺志 | 一种新型药茶的生产方法 |
CN1895557A (zh) * | 2006-06-28 | 2007-01-17 | 陈志忠 | 一种治疗高血压、高血脂、高血糖的中草药剂 |
CN102949615A (zh) * | 2012-12-04 | 2013-03-06 | 南通瑞鑫电子电器有限公司 | 一种治疗高血压的药 |
CN103041070A (zh) * | 2012-12-31 | 2013-04-17 | 青岛华仁信息技术开发有限公司 | 一种银杏叶降脂降压保健品及其制备方法 |
CN103120766A (zh) * | 2013-01-29 | 2013-05-29 | 柴伟利 | 一种治疗高血压的中药组合物 |
-
2013
- 2013-09-28 CN CN201310461769.9A patent/CN103721094B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095952A (zh) * | 1993-06-04 | 1994-12-07 | 陈顺志 | 一种新型药茶的生产方法 |
CN1895557A (zh) * | 2006-06-28 | 2007-01-17 | 陈志忠 | 一种治疗高血压、高血脂、高血糖的中草药剂 |
CN102949615A (zh) * | 2012-12-04 | 2013-03-06 | 南通瑞鑫电子电器有限公司 | 一种治疗高血压的药 |
CN103041070A (zh) * | 2012-12-31 | 2013-04-17 | 青岛华仁信息技术开发有限公司 | 一种银杏叶降脂降压保健品及其制备方法 |
CN103120766A (zh) * | 2013-01-29 | 2013-05-29 | 柴伟利 | 一种治疗高血压的中药组合物 |
Non-Patent Citations (1)
Title |
---|
刘学义: ""中西医结合治疗高血压疾病的进展"", 《中国医药指南》, vol. 10, no. 20, 31 July 2012 (2012-07-31) * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104258135A (zh) * | 2014-09-23 | 2015-01-07 | 苏州市天灵中药饮片有限公司 | 用于降血压降血脂的保健软胶囊及其制备方法 |
CN104304596A (zh) * | 2014-11-16 | 2015-01-28 | 久美彭措 | 一种采用食用植物作为成分组合而成的降血糖代用茶的制备方法 |
CN105012385A (zh) * | 2015-07-28 | 2015-11-04 | 红河州吉昌生物科技有限公司 | 改进型补肝肾降血压胶囊 |
CN109953152A (zh) * | 2017-12-22 | 2019-07-02 | 甘肃渭水源药业科技有限公司 | 一种用黄芪花作原料的花茶及其制备方法 |
CN108617818A (zh) * | 2018-08-16 | 2018-10-09 | 李文霞 | 一种降血压的保健茶 |
Also Published As
Publication number | Publication date |
---|---|
CN103721094B (zh) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103721094B (zh) | 用于降血压的保健茶 | |
CN104606513A (zh) | 一种治疗心脑血管疾病的中药及其制备方法 | |
CN104206594A (zh) | 一种降压降脂的桑寄生保健茶及其制备方法 | |
CN104815192A (zh) | 一种治疗高血压的药物组合物及其应用 | |
CN104906403A (zh) | 一种降压降脂的罗布麻叶保健口服液及其制备方法 | |
CN104815232A (zh) | 一种治疗原发性肺动脉高压的中药制剂及其制备方法 | |
CN104432386B (zh) | 一种防治腰膝酸软、筋骨无力的桑寄生口服液及其制备方法 | |
CN103432274B (zh) | 一种治疗偏头痛的药物及其制备方法 | |
CN104689240A (zh) | 一种治疗气滞血瘀型黄褐斑的药物及其制备方法 | |
CN104758572A (zh) | 一种治疗痰饮阻肺型心功能不全的药物及其制备方法 | |
CN104689125A (zh) | 一种治疗沙眼的药物及其制备方法 | |
CN104223062B (zh) | 一种降压降糖的地骨皮保健口服液及其制备方法 | |
CN104225423B (zh) | 一种治疗前列腺炎的药物组合物及其制备方法 | |
CN105381285A (zh) | 中药复合降压保健茶 | |
CN103721182A (zh) | 用于治疗高血压的中药组合物 | |
CN105816554A (zh) | 一种治疗抑郁症的中药组合物 | |
CN105327145A (zh) | 治疗高血压性脑出血的组合物及其制备方法 | |
CN105343394A (zh) | 一种治疗高血压的中药组合物 | |
CN104258135A (zh) | 用于降血压降血脂的保健软胶囊及其制备方法 | |
CN104547643A (zh) | 一种用于治疗高血压的中药组合物 | |
CN104225506A (zh) | 用于治疗化疗后血小板减少的药物制剂 | |
CN103520644A (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN108159365A (zh) | 一种用于治疗冠心病心肌缺血的中药组合物及其制备方法 | |
CN107715077A (zh) | 一种治疗心悸的中药组合物及其制备方法 | |
CN104258202A (zh) | 一种治疗气血亏损型高血压的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160617 Address after: Qingdao City, Shandong province 266033 Taiwan Liu Road No. 138 B Applicant after: Yang Gaolin Address before: 266071 Shandong city of Qingdao province Hongkong City Road No. 32 Minmetals building room 801-A Applicant before: Qingdao Huaren Technology Incubator Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 542899 No. 25 Jianshe Middle Road, the Guangxi Zhuang Autonomous Region, Hezhou Patentee after: Yang Gaolin Address before: Qingdao City, Shandong province 266033 Taiwan Liu Road No. 138 B Patentee before: Yang Gaolin |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180529 Address after: 511401 304, room 3, Longji building, 16 Ping Kang Road, Panyu District, Guangzhou, Guangdong. Patentee after: Guangzhou Zhonghui agricultural science and Technology Co., Ltd. Address before: 542899 No. 25 Jianzhong Road, Hezhou, the Guangxi Zhuang Autonomous Region. Patentee before: Yang Gaolin |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160713 Termination date: 20180928 |